polyvalent vaccine-KLH conjugate
Fallopian Tubes Cancer
Memorial Sloan Kettering Cancer CenterN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
125 Active assets in the Fallopian Tubes Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mirvetuximab Soravtansine AbbVie | Phase 3 | BB |
Inno-206 Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BB |
Irinotecan Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
Carboplatin Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | BB |
Hycamtin Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
polyvalent vaccine-KLH conjugate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →